Dr Reddy’s launches oral semaglutide tablet Obeda for diabetes patients in India
Dr. Reddy's Laboratories on Tuesday announced the launch of its oral semaglutide biosimilar tablet, branded as Obeda®, for the treatment of type 2 diabetes mellitus in India. The Hyderabad-based pharmaceutical major said the launch strengthens its position in the growing GLP-1 therapies segment fol...
